Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Quark and Suzhou Ribo Start China Trial of Anti-Blindness RNAi Drug

publication date: Mar 15, 2016
Quark Pharma, a US-Israeli developer of RNA-interference drugs, has begun a global Phase II/III trial of its siRNA treatment for blindness, including a China arm. Two years ago, Quark established a China JV with Suzhou Ribo Life Science to develop the drug in China, funded with $7.5 million in venture capital. Quark said the approval is the first in China for an RNAi drug. QPI-1007 seeks to prevent deterioration of the optic nerve, a condition known as non-arteritic anterior ischemic optic neuropathy (NAION). More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital